CONFERENCE DIRECTORS
William Caceres, M.D.
Associate Professor, Internal Medicine
Universidad Central del Caribe School of Medicine
Luis E. Raez, M.D., FACP, FCCP
Director, Memorial Cancer Institute
Clinical Associate Professor of Medicine
Herbert Wertheim College of Medicine
Florida International University
Edgardo S. Santos, M.D., FACP
Medical Director of Cancer Research
Thoracic and Head and Neck Cancer Programs
Associate Professor of Biomedical and Clinical Science
Florida Atlantic University
San Juan, PR
Miami, Florida
Lynn Cancer Institute
Boca Raton, Florida
CONFERENCE DESCRIPTION
This is a three day course designed for medical oncologists, radiation oncologists, surgical oncologists, advanced registered nurse practitioners (ARNP), physician assistants (PA), oncology nurses, registered pharmacists, pharmacy technicians, and radiation therapists. General practitioners (internal medicine and family medicine) will have the benefit of a review of the standard of care and new developments in cancer therapy. Residents in training and fellows from these specialties are encouraged to attend. Topics in breast cancer, gastrointestinal (GI) malignancies, head and neck cancers, hematological malignancies (i.e., multiple myeloma, CLL, CML, and Non-Hodgkin’s lymphoma), genito-urinary cancers (GU), brain tumors, malignant melanoma, and non small cell lung cancer (NSCLC) will be presented. There will also be a special session devoted to supportive of care in oncology such as management of emesis, as well as management of side effects from novel immunotherapy therapy agents. The areas of focus for this conference will include the review of current standards of care in the treatment of all malignancies and new developments in cancer care. There will be an emphasis on molecular diagnosis and individualization of cancer therapy based on molecular profiles. Presentations from latest national (ASCO 2016 or ASH 2015) and International (ESMO 2016) meetings will be reviewed and guidelines of cancer care will be emphasized. The participants in the meeting will have a chance not only to hear outstanding reviews of these topics but also personal interaction with our oncology experts in the field during our questions and answer sessions.
CONFERENCE OBJECTIVES
Upon completion of this course attendees will be able to:
- Understand the latest advances in chemotherapy treatments in the areas of lung cancer, breast cancer, prostate, gastrointestinal malignancies, and others as well as hematological malignancies (CLL, CML, multiple myeloma, non-Hodgkin Lymphoma).
- Apply genetic and biomarker testing to personalize therapy in malignant diseases and evaluate the current standards of care in the treatment of several cancer diagnoses.
- Recognize the clinical indications, risks and benefits of combined modality treatments for NSCLC, head and neck, gastrointestinal malignancies, breast cancer and some hematological malignancies..
- Identify and treat complications related to the disease process, chemotherapy and novel biological agents by applying the proper use of supportive care and on time acute interventions.
- Discuss novel tumorigenesis pathways as potential target for drug development as well as immunologic manipulation as a mechanism to fight against different tumor types.
REGISTRATION
Registration fee:
- $150 Physicians
- $75 Nurses, Nurse Practitioners, Physician Assistant and Allied Health Professionals
- $250 Industry Professionals
Registration fee includes all day admission to the Friday and Saturday scientific presentation. Refunds must be provided in writing prior to October 14, 2016. After October 14, 2016 no Refunds will be provided. All refunds will be charged a $50.00 administrative fee.
Register online at www.meccinc.com
